Try our Advanced Search for more refined results
Life Sciences - December, 2016
235 articles
- 6 Key Commercial Litigation Finance Trends For 2017
- 5 Ways To Fight Costlier Legal Malpractice Claims In 2017
- NJ Tax Judge Limits Access To Merck Property Sale Deal
- EU Unified Patent Court Will Proceed In 2017 — Now What?
- Mediating E-Discovery Disputes Can Save Time And Money
- Feds Push Through Record FCPA Week With Teva Case
- Supplement Co. Says Venable Can't Rep Foe In False Ad Row
- Insys Seeks Delay, Toss Of Investor Drug Plot Suit In Del.
- Doctor In Testosterone Gel MDL Must Reveal Drug Co. Deals
- Bio-Rad Can't Block Ex-GC's Evidence In Retaliation Trial
- Judge Backs Widow's Objection To GSK Trial Documents
- NJ Justices Won't Hear Ex-Merck Worker's Sex Bias Suit
- Ethicon Pushes Supreme Court To Hear AIA Process Case
- Schwarzenegger Supplement Maker, Rival Drop Ad Claim Suit
- Takeaways From China's Antitrust Case Against Medtronic
- New Obama Innovation Hub Targets Artificial Skin For Soldiers
- 5 Trends That Shaped The IPO Landscape In 2016
- Implied Preemption And Monograph Drugs: Part 2
- Teva Pharmaceutical To Pay $519M To Settle FCPA Charges
- Firms Fight For Equal Fees In $785M Pfizer FCA Deal
- Where 5 Top MDLs Stand At The End Of 2016
- Taro, Perrigo Hit With Price-Fixing Suit Over Skin Cream
- Bernstein Litowitz Ducks Subpoena In Insider Trading Row
- Celebrex Judge OKs $468M Settlement, $130M In Fees
- Warner Chilcott Urges Judge To Nix Asacol Antitrust Claims
- Implied Preemption And Monograph Drugs: Part 1
- Diet Pill Co., Snooki Ask To End Buyers' Zantrex False Ad Suit
- Breast Implant Maker To Pay $10.9M To End Securities Suit
- Bovine Sperm Co. Gets Genetics Patent Claim Nixed
- The Future Of Legal Marijuana: Post-Election Outlook
- State AGs May Turn Up Enforcement Under Trump
- Avoid Inadvertent Tipping This Holiday Season
- Building Momentum For The Pay Equity Movement In BigLaw
- Are You Prepared For A 'Post-Fact' Jury?
- Arnold & Porter, GE Counsel Hit With DQ Bid In IP Row
- Amphastar Urges 1st Circ. To Nix Rivals' Antitrust Immunity
- Allergan To Acquire Acelity-Owned LifeCell For $2.9B
- Calif. Attys' Press Statements Protected By Anti-SLAPP
- Tokai Hopes To Move $97M Suit Over IPO To Mass. Fed. Court
- 3rd Circ. Tosses Starch Co.'s Challenge To IP Rights Award
- $1B Verdict In J&J Hip Implant Bellwether Up For Judge's OK
- Stryker Must Face Sanctions For Frivolous Filing, Judge Told
- Pharmaceutical Formulations: Ready For Patenting?
- Teva Accuses Mylan, Others Of Infringing Copaxone Patent
- Deals Rumor Mill: Sanofi, Bright Food, Huawei Technologies
- US Solicitor Sides With Sandoz In Biosimilar Case
- Teva, Actavis, Sandoz Hit With Skin Cream Price-Fixing Suit
- BioZone Founder's Backbiting Breached Deal, Judge Told
- Judge Wrongly Limited Meningitis Outbreak Trial, Gov't Says
- Stryker Adds Patients To $1B Hip Implant Settlement
- Med Device Co. Can't Claim Extra Investment Grant
- Medical Laser Co. Lensar Hits Ch. 11 After IP Settlement
- 10th Circ. Won't Block Utah Contact Lens Pricing Law
- Shkreli's Ex-Atty Can't Get More Details On Fraud Charges
- Ex-Maquet Compliance Officer Files Whistleblower Suit
- EQT Inks €2.74B Sale Of BSN Medical
- Kite Hit With Suit After PTAB Upholds Cancer Therapy Patent
- Keeping Pro Se Litigants At Bay
- Kimberly-Clark Denied Bid For Delay In Gown Suit
- 21st Century Cures Act Benefits Biopharma Co. Data Use
- Ex-Cyberonics Sales Rep Can't Bring FCA Suit: 1st Circ.
- 11th Circ. Affirms Denial Of Fees In Legal Malpractice Row
- Drug Cos. Say Chicago's Opioid Claims Still Miss The Mark
- Pfizer And Subsidiaries Shake FCA Pain Patch Suit
- Rembrandt Urges High Court To Skip Expert Misconduct Case
- Reed Smith Widow Slams GSK's 'Mountain' Of Trial Exhibits
- 7th Circ. Sticks Surgical Tools Co. With Predecessor Tax Bill
- FDA Removes Chantix Warning About Suicidal Thoughts
- UK Antitrust Watchdog Accuses Actavis Of Excessive Pricing
- Mylan's Generic EpiPen Launches At Half The Price
- Health Hires: McCarter & English, Arent Fox, Nossaman
- Biotech Needn't Disclose Sponsored News, 11th Circ. Says
- Are Courts In The Discovery Driver's Seat?
- DaVita Gets Some Dialysis Death Claims Tossed
- Jury Finds Perrigo Infringed Pepcid Patent, Must Pay $10M
- 4 Key Takeaways From The DOJ's $4.7B FCA Haul
- Alere Granted Discovery After Abbott Seeks To Kill Merger
- Valeant Offering Needn't Meet Public Standards, SIFMA Says
- Covidien, Agency Urge Justices To Skip AIA Process Case
- Deals Rumor Mill: Verizon, Sanofi, Garena
- $38M FCA Payout Ends Kickback Suit Against Forest Labs
- FDA Hammers 2 More Drugmakers Over Bad Ads
- Masimo Says Rival's Blood Exam Patents Test Negative
- Idenix Wins $2.5B Verdict In Gilead Hep C Drug Patent Fight
- Takeda IP Suit Over Hikma Gout Flare Drug Is Reopened
- Amgen, Pfizer Sanction Bid Stirs Judge's Ire In Infection Row
- Pharmacy Execs Score Separate Trials Over Deadly Outbreak
- Lonza Snaps Up KKR-Backed Capsugel In $5.5B Deal
- Fujifilm To Expand Health Care Biz With $1.3B Wako Buy
- FDA Regulation Of Laboratory Developed Tests: A Long Saga
- Life Sciences MVP: Sullivan's Krishna Veeraraghavan
- 20 States Sue Generic-Drug Companies Over Collusion
- 6 Ways IP Enforcement Plan Impacts Public Health And Safety
- Endo's False Ad Claims Against Actavis Tossed For Good
- Life Sciences MVP: Paul Weiss' Catherine Nyarady
- Baxter Wins Bid To Keep Dechert Docs From Insurer
- Direct Buyers Push 1st Circ. To Rethink Nexium Suit
- FDA Scolds Celgene, Sanofi For Cluttered TV Ads
- Baxter, Hospira Fixed Saline Prices, Pa. Hospital Says
- NYC To Create $100M Life Sciences Campus
- 2nd Circ. Judge Worried Icahn Trade Tactic Reaps 'Zillions'
- Judge Wants More Info From Fresenius Dialysis Patients
- Alleged Health Fraud Ringleader Held After Making Threats
- FCA Crackdown Nets $4.7B In 2016, Capping Historic Run
- Colgate-Using Judge Can Stay On False Ad Suit, Co. Says
- Inciting Innovation In Drug And Medical Device Development
- Judge OKs Jury Trial In Ferring False Ad Row Over Drug
- DOJ Charges 2 Execs In Generic Drug Price-Fixing Plot
- The Outlook On Drug Pricing: At What Cost?
- Greatbatch Can't Hike Damages After Patent Win Against AVX
- Non-Residents' Plavix Row Belongs In Calif., High Court Told
- Anesthesia Firm Investor Says Board Has Entrenched Itself
- La. Tells 3rd Circ. It's Not Part Of GSK Antitrust Settlement
- Ex-InterMune Exec Says Salman Voids Insider Trading Loss
- Rules Of Civil Procedure Updates Affect E-Discovery
- Philly Judge Junks J&J Risperdal Case Midtrial
- CPSC Civil Penalties: Setting New Records In 2016
- The Path To The California Bench
- Indivior Wants States' Suboxone Product-Hop Claims Nixed
- OPINION: The ITC's Opportunity To Seize The Moment
- SEC Says Bio-Rad Wrong To Call Ex-GC's Work Privileged
- BigLaw Alums Q&A: Capital Appellate's Larry Ebner
- Life Sciences MVP: Latham & Watkins' John Manthei
- Buyers Want 1st Circ. To Rethink Nexium Pay-For-Delay Suit
- 3 Tips To Avoid Being On The Outs With In-House Counsel
- Staar Surgical Investors Seek Class Cert. In Stock-Drop Row
- GSK, Nev. Abused Fed. Drug Discount Program, 9th Circ. Told
- High Court Biosimilar Drama Intact After Amgen-Apotex Denial
- Kasowitz Can't Use FCA For Unlevied Fines: Chem Cos.
- Deals Rumor Mill: 21st Century Fox, Lonza, Sabeco
- Arthrex Wins $17M Verdict In Surgery Implant Patent Suit
- Bayer, Versant Invest $225M In Stem Cell Venture
- Facing $91M IP Judgment, Neovasc To Sell Facility
- Kansas Class To Lead Lanham Act Trial In Syngenta MDL
- Life Sciences MVP: Kirkland & Ellis' Jay Lefkowitz
- Hagens Berman Says Special Master Inquiry Risks Privilege
- Express Scripts Says Stockholder Suit Lacks Fraud Proof
- PTAB Agrees To Review Allergan Restasis Patents
- Women In Mesh MDL Must Show Safer Design Was Feasible
- Life Sciences MVP: White & Case's J. Mark Gidley
- Vitamin Co. Can't Shake 'Made In USA' Suit, Consumer Says
- JPML Centralizes J&J Invokana Unit Litigation In N.J.
- FTC Says Boehringer Should Cough Up Pay-For-Delay Docs
- Pharmacy Execs Want Separate Trials Over Deadly Outbreak
- Deals Rumor Mill: PPD, CCP, Time
- The Horrible Conflict Between Biology And Women Attorneys
- Boston Scientific Wages IP Suit Against Nevro's Pain Device
- Diet Pill Maker Seeks Sanctions For FTC Witness's Husband
- Sanofi Can't Enforce Deal It Broke In $20M Suit, Elorac Says
- How Latin America Is Stepping Up Anti-Corruption Efforts
- The Top Product Liability Cases Of 2016: Year-End Report
- FTC And Courts Remain Real Serious About Fake News Ads
- 3rd Circ. Won't Rethink Nixing Of Law Firm's Risperdal Suit
- Novartis Loses At BALCA In Case Over Exec. Director Job
- Ex-Insys Executives Charged In Painkiller Kickback Scheme
- Fed. Circ. Upholds Toss Of Plastic-Product Packaging IP
- Grifols Accused Of Off-Label Drug Uses In FCA Suit
- Hemispherex Investors Put Anti-Fatigue Drug Suit To Rest
- Atty DQ Sought In Medical Supplier Trademark Row
- Bristol-Myers Squibb To Pay $19.5M Over Abilify Marketing
- Lawyer EQ: Finding Success In Every Interaction
- FCA Decision Tracker: Continued Interpretations Of Escobar
- Inside The 2nd Circ. Ruling In Abbott V. Adelphia
- Managing Intergenerational Differences Within Your Law Firm
- Reliable Analysis Is Key To Addressing Ascertainability
- NY Firm, Ex-Client Ask 11th Circ. To Fix Jury's Errors
- Medical Group Pays $9.3M To Settle TCPA Junk Fax Claims
- Fed. Circ. Says PTAB Didn't Explain Itself In NuVasive Review
- GNC Agrees To Pay $2.3M Over Mislabeled Supplements
- Congress Passes Major Pharmaceutical Reform Bill
- The FTC's Overreaching Regulation Of Homeopathic Drugs
- Doc Says Bayer Axed Her For Backing Pregnant Worker
- Bayer Gets Win In Dentist's Antibiotic-Damage Suit
- Talking 'Bull': Episode 8, Too Perfect
- Colitis Drug Buyers Fight Doc Requests In Antitrust Row
- Pfizer Fined $106M Over Price Of Epilepsy Drug In UK
- House To Vote For Funding Bandage To Hold Gov't Until April
- Deals Rumor Mill: Bayer, Pandora, Montagu Private Equity
- Patients Urge 7th Circ. To Keep Eye Drop Class Cert.
- Philip Hirschkop: Quietly Making Noise For 50 Years
- Abbott Asks Chancery Court To Kill $5.8B Alere Buyout
- FDA Warning Wire: Agency Sour On Juice Health Claims
- Justices Wary Of Complicated Rule In Patent-Export Case
- Gilead Uses Merck As Shield In $2.5B Idenix Patent Fight
- Forest Blasts Attys' 'Shameful' Conduct In FCA Suit
- Congress Passes Health Care Access Data Bill
- Novo Nordisk Pledges To Limit Drug Price Increases
- NJ Justices Won't Review $11M J&J Pelvic Mesh Bellwether
- Supplement Buyer Stands Behind False Ad Accusations
- Medicines Co. Gets Fed. Circ. Grilling On Blood Thinner IP
- Vitamin Co. Says 'Made In USA' Cert. Bid Lacks Evidence
- Momenta Asks 1st Circ. To Affirm Enoxaparin Suit Immunity
- Idenix Seeks $2.5B In Gilead Hep C Drug Patent Dispute
- Promega IP Case May Portend More Liability For Exporting Cos.
- Apotex Can't Ditch Subpoena From Sandoz, Court Says
- Major Pharmaceutical Reform Bill Taken Up By Senate
- Watson Labs Urges Justices To Keep 'On Sale' Bar Intact
- New Atty's Scheduling Mixup Not Court's Problem, Judge Says
- Insurers Must Pay Counterclaims, Mass. High Court Told
- ITC To Investigate PacBio's DNA Sequencer Patent Claim
- Aegerion To Pay Investors $22M In Juxtapid Marketing Row
- Drug Cos. Urge High Court To Nix State Law Claims On Reglan
- Deals Rumor Mill: Sanofi, Northland Power, Sirius XM
- J&J Asks 1st Circ. To Halt Hip Implant FCA Suit
- Offshore Patent Transfer Payments Draw IRS, Court Scrutiny
- Cannabis Industry Faces Budding Product Liability Issues
- PTAB Rejects Dr. Reddy's Challenges To Suboxone Patents
- Stryker Asks 6th Circ. To Rethink $8.6M Coverage Loss
- Payor Swings Back At GSK Sanctions Bid In Avandia MDL
- The Causation Question Left Unanswered By Actavis
- Huge Verdicts Won't Spur Settlement Talks In J&J Hip MDL
- Allergan Strikes Deal With Zydus In Colitis Drug IP Suit
- 5th Circ. Reverses $340M Antitrust Ruling Against Syringe Co.
- Simpson Thacher Leads Teleflex $1B Vascular Solutions Deal
- J&J Faces Risperdal Claims For 6th Time In Philadelphia
- Insurer Must Pay $15M For Toxic Vitamin Class Settlement
- PTAB Rejection Of Microscope Device IP Upheld By Fed. Circ.
- Deals Rumor Mill: PAI Partners, Ladder Capital, Fitbit
- Mass. Appeals Court Nixes Drug Royalty Suit
- Eli Lilly Challenges Apotex's Proposed Cialis Generic
- Plaintiffs Seek Consolidation In Meningitis Outbreak Case
- 5 Insights From Airbus Group's Joshua Walker
- Safeway Must Face Inflated Drug Price Suit
- University Wants Unpaid Patent License Fees Suit Revived
- Rite Aid Can't Demand Union Remove Staff, Judge Says
- Allergan Sues Drugmakers Over Linzess Generics
- FDA Smacks Down Vanda's Bid To Block Fanapt Generics
- Attys Lose $35K Fee After 7th Circ. Orders New Analysis
- Experts Hampered In Depakote Birth Defect Trial, Mom Says
- CORRECTED: Novartis Knocks Colombia Over Leukemia Drug Price Control
- PTAB Finds Covidien Surgical Instrument Patent Invalid
- Fat-Freezing Licensee Says Spa Is Infringing
- 3rd J&J Hip Implant Bellwether Delivers $1B Verdict
- What's At Stake In High Court's Life Tech Patent Case
- Despite Momentum, Marijuana Remains Risky Business